Viracta Therapeutics Share Holder Equity 2010-2024 | VIRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Viracta Therapeutics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Viracta Therapeutics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.8B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.1B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$14B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12B
Catalent (CTLT)	$11.1B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$6B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.2B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.6B
Evotec AG (EVO)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Indivior (INDV)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B
Ocular Therapeutix (OCUL)	$1.4B